Literature DB >> 11466625

Oncogenic transformation induced by membrane-targeted Akt2 and Akt3.

I Mende1, S Malstrom, P N Tsichlis, P K Vogt, M Aoki.   

Abstract

The kinases Akt2, Akt3 and their myristylated variants, Myr-Akt2 and Myr-Akt3 were expressed by the RCAS vector in chicken embryo fibroblasts (CEF). Myr-Akt2 and Myr-Akt3 were strongly oncogenic, inducing multilayered foci of transformed cells. In contrast, wild-type Akt2 and Akt3 were only poorly transforming, their efficiencies of focus formation were more than 100-fold lower; foci appeared later and showed less multilayering. Addition of the myristylation signal not only enhanced oncogenic potential but also increased kinase activities. Myr-Akt2 and Myr-Akt3 also induced hemangiosarcomas in the animal, whereas wild type Akt2 and Akt3 were not oncogenic in vivo. Furthermore, Akt2, driven by the lck (lymphocyte specific kinase) promoter in transgenic mice, induced lymphomas. The oncogenic effects of Akt2 and Akt3 described here are indistinguishable from those of Akt1. The downstream targets relevant to oncogenic transformation are therefore probably shared by the three Akt kinases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466625     DOI: 10.1038/sj.onc.1204486

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Authors:  Yongping Shao; Andrew E Aplin
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 3.  The survival kinases Akt and Pim as potential pharmacological targets.

Authors:  Ravi Amaravadi; Craig B Thompson
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis.

Authors:  Jonathan E McDunn; Jared T Muenzer; Latif Rachdi; Katherine C Chang; Chris G Davis; W Michael Dunne; David Piwnica-Worms; Ernesto Bernal-Mizrachi; Richard S Hotchkiss
Journal:  FASEB J       Date:  2007-09-13       Impact factor: 5.191

5.  Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus.

Authors:  S Malstrom; E Tili; D Kappes; J D Ceci; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Integrin-dependent Akt1 activation regulates PGC-1 expression and fatty acid oxidation.

Authors:  Craig C Beeson; Gyda C Beeson; Haley Buff; Juanita Eldridge; Aiguo Zhang; Arun Seth; Marina Demcheva; John N Vournakis; Robin C Muise-Helmericks
Journal:  J Vasc Res       Date:  2012-01-13       Impact factor: 1.934

7.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Authors:  Michael G Kharas; Rachel Okabe; Jared J Ganis; Maricel Gozo; Tulasi Khandan; Mahnaz Paktinat; D Gary Gilliland; Kira Gritsman
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  A dominant interfering Bub1 mutant is insufficient to induce or alter thymic tumorigenesis in vivo, even in a sensitized genetic background.

Authors:  Dale O Cowley; Ginger W Muse; Terry Van Dyke
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.

Authors:  Roman A Timakhov; Yinfei Tan; Mamta Rao; Zemin Liu; Deborah A Altomare; Jianming Pei; David L Wiest; Olga O Favorova; Janice E Knepper; Joseph R Testa
Journal:  Genes Chromosomes Cancer       Date:  2009-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.